Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions

American Journal of Health-System Pharmacy

Volumn 69, Issue 16, 2012, Pages 1405-1409

  LaPlante, Kerry L ^a,b   Woodmansee, Suzanne ^c   Mermel, Leonard A ^b,d  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRATE SODIUM; HEPARIN; TELAVANCIN; VANCOMYCIN;

ANALYSIS OF VARIANCE; ARTICLE; BLOOD CLOTTING; CATHETER INFECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SOLUTION; DRUG STABILITY; FREEZE DRYING; HUMAN; HUMAN TISSUE; INJECTION; LIMIT OF QUANTITATION; PARTIAL THROMBOPLASTIN TIME; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; ROOM TEMPERATURE;

EID: 84865970503     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110256     Document Type: Article

References (21)

1. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49:1-45. [Errata, Clin Infect Dis. 2010; 50:457,1079 (dosage error in text).]
2. O'Grady NP, Alexander M, Burns LA et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011; 52:e162-93.
3. Attwood RJ, LaPlante KL. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health-Syst Pharm. 2007; 64:2335-48. (Pubitemid 350174705)
4. Kosowska-Shick K, Clark C, Pankuch GA et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother. 2009; 53:4217-24.
5. Krause KM, Renelli M, Difuntorum S et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother. 2008; 52:2647-52. (Pubitemid 351915701)
6. Vibativ (telavancin) for injection, for intravenous use. www.astellas.us/docs/us/VIBATIV-PI-Final.pdf (accessed 2010 Feb 9).
7. Capdevila JA, Segarra A, Planes AM et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Transplant. 1993; 8:231-4. (Pubitemid 23122974)
8. Krähenbuhl-Melcher A, Schlienger R, Lampert M et al. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007; 30:379-407.
9. LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant. 2007; 22:2239-46. (Pubitemid 47248465)
10. Dasta JF, Hale KN, Stauffer GL et al. Comparison of visual and turbidimetric methods for determining short-term compatibility of intravenous critical-care drugs. Am J Hosp Pharm. 1988; 45:2361-6. (Pubitemid 19030727)
11. Goldberg MR, Wong SL, Shaw JP et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy. 2010; 30:35-42.
12. Bastani B, Amin K, Herr A. Prolonged stability of stored vancomycin, gentamicin, and heparin for use in the antibioticlock technique. ASAIO J. 2005; 51:761-3. (Pubitemid 44366140)
13. Battistella M, Walker S, Law S et al. Antibiotic lock: in vitro stability of vancomycin and four percent sodium citrate stored in dialysis catheters at 37 degrees C. Hemodial Int. 2009; 13:322-8.
14. Robinson JL, Tawfik G, Saxinger L et al. Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy. J Antimicrob Chemother. 2005; 56:951-3. (Pubitemid 41631925)
15. Krishnasami Z, Carlton D, Bimbo L et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int. 2002; 61:1136-42. (Pubitemid 34175482)
16. Poole CV, Carlton D, Bimbo L et al. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Nephrol Dial Transplant. 2004; 19:1237-44. (Pubitemid 38628145)
17. Vardhan A, Davies J, Daryanani I et al. Treatment of haemodialysis catheter-related infections. Nephrol Dial Transplant. 2002; 17:1149-50.
18. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ et al. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant. 2002; 17:2189-95. (Pubitemid 35446677)
19. Food and Drug Administration. FDA issues warning on tricitrasol. www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm173095.htm (accessed 2012 Mar 12).
20. Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2007; 60:406-9. (Pubitemid 47243894)
21. LaPlante KL, Mermel LA. In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother. 2009; 53:3166-9.